EXEL
Neutral signalScored 2026-08-14 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Exelixis, Inc.
- Nom
- Exelixis, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $16.3B
- Employés
- 1,077
- PDG
- Michael Morrissey
- Site web
- https://www.exelixis.com
- Marché
- ALPMYAZNCRISGMABHCMINCY
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 9 812 titres (~526 511,92 $ US)
- Insiders
- Beckerle Mary C
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$526,512
Avg sell (VWAP, 90d window) $53.66 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$526,512 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C | Sell · S · 10b5-1 | 9,812 | $53.66 | $526,512 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2024-01-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2019-06-04 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-04-16 | Donna Shalala | Sale (Partial) | $1,001 - $15,000 |
| 2019-02-06 | Donna Shalala | Purchase | $1,001 - $15,000 |
| 2019-01-09 | Donna Shalala | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-14 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $527K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $527K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 3.56 · operating margin 38%
Market snapshot
Financial ratios
| Metric | Trend | 2026-01-02 | 2025-01-03 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | |
| Ebit Margin | 38.5% | 31.8% | 14.1% | 14.5% | 20.5% | |
| Ebitda Margin | 39.7% | 33.1% | 15.5% | 15.8% | 21.4% | |
| Operating Profit Margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | |
| Pretax Profit Margin | 40.6% | 31.4% | 14.1% | 14.5% | 20.5% | |
| Continuous Operations Profit Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | |
| Net Profit Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | |
| Bottom Line Profit Margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | |
| Current Ratio | 3.558 | 3.635 | 3.343 | 4.991 | 5.435 | |
| Quick Ratio | 3.505 | 3.579 | 3.299 | 4.888 | 5.353 | |
| Solvency Ratio | 1.188 | 0.782 | 0.344 | 0.348 | 0.603 | |
| Cash Ratio | 1.189 | 0.538 | 0.667 | 1.545 | 1.917 | |
| Price To Earnings Ratio | 15.132 | 18.872 | 36.908 | 28.140 | 25.041 | |
| Price To Earnings Growth Ratio | 0.252 | 0.107 | 2.630 | -1.284 | 0.244 | |
| Forward Price To Earnings Growth Ratio | 0.252 | 0.107 | 2.630 | -1.284 | 0.244 | |
| Price To Earnings Diluted Ratio | 15.676 | 19.301 | 36.908 | 28.643 | 25.389 | |
| Price To Earnings Diluted Growth Ratio | 0.270 | 0.113 | 2.296 | -1.289 | 0.240 | |
| Price To Book Ratio | 5.476 | 4.390 | 3.371 | 2.073 | 2.604 | |
| Price To Sales Ratio | 5.101 | 4.543 | 4.170 | 3.201 | 4.011 | |
| Price To Free Cash Flow Ratio | 14.017 | 15.545 | 44.803 | 23.007 | 17.102 | |
| Price To Operating Cash Flow Ratio | 13.384 | 14.075 | 22.898 | 14.222 | 14.361 | |
| Debt To Assets Ratio | 0.061 | 0.065 | 0.065 | 0.062 | 0.020 | |
| Debt To Equity Ratio | 0.080 | 0.085 | 0.084 | 0.076 | 0.023 | |
| Debt To Capital Ratio | 0.074 | 0.078 | 0.077 | 0.071 | 0.023 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.316 | 1.313 | 1.300 | 1.234 | 1.183 | |
| Working Capital Turnover Ratio | 2.208 | 2.182 | 1.650 | 1.154 | 1.048 | |
| Operating Cash Flow Ratio | 2.180 | 1.734 | 0.845 | 1.118 | 1.187 | |
| Operating Cash Flow Sales Ratio | 0.381 | 0.323 | 0.182 | 0.225 | 0.279 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.955 | 0.905 | 0.511 | 0.618 | 0.840 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 5.110 | 3.668 | 1.755 | 1.907 | 7.817 | |
| Capital Expenditure Coverage Ratio | 22.147 | 10.576 | 2.045 | 2.619 | 6.241 | |
| Dividend Paid And Capex Coverage Ratio | 22.147 | 10.576 | 2.045 | 2.619 | 6.241 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 12.504 | 13.671 | 26.689 | 18.988 | 16.766 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 96.4% | ▼-0.1% | ▲0.1% |
| Ebit Margin | 38.5% | ▲6.7% | ▲14.6% |
| Ebitda Margin | 39.7% | ▲6.6% | ▲14.6% |
| Operating Profit Margin | 37.6% | ▲9.7% | ▲16.1% |
| Pretax Profit Margin | 40.6% | ▲9.1% | ▲16.3% |
| Continuous Operations Profit Margin | 33.7% | ▲9.7% | ▲14.4% |
| Net Profit Margin | 33.7% | ▲9.7% | ▲14.4% |
| Bottom Line Profit Margin | 33.7% | ▲9.7% | ▲14.4% |
| Current Ratio | 3.558 | ▼-0.077 | ▼-0.634 |
| Quick Ratio | 3.505 | ▼-0.075 | ▼-0.620 |
| Solvency Ratio | 1.188 | ▲0.406 | ▲0.535 |
| Cash Ratio | 1.189 | ▲0.651 | ▲0.018 |
| Price To Earnings Ratio | 15.132 | ▼-3.740 | ▼-9.687 |
| Price To Earnings Growth Ratio | 0.252 | ▲0.145 | ▼-0.138 |
| Forward Price To Earnings Growth Ratio | 0.252 | ▲0.145 | ▼-0.138 |
| Price To Earnings Diluted Ratio | 15.676 | ▼-3.625 | ▼-9.507 |
| Price To Earnings Diluted Growth Ratio | 0.271 | ▲0.158 | ▼-0.056 |
| Price To Book Ratio | 5.476 | ▲1.086 | ▲1.893 |
| Price To Sales Ratio | 5.101 | ▲0.558 | ▲0.896 |
| Price To Free Cash Flow Ratio | 14.017 | ▼-1.528 | ▼-8.878 |
| Price To Operating Cash Flow Ratio | 13.384 | ▼-0.692 | ▼-2.404 |
| Debt To Assets Ratio | 0.061 | ▼-0.004 | ▲0.006 |
| Debt To Equity Ratio | 0.080 | ▼-0.005 | ▲0.010 |
| Debt To Capital Ratio | 0.074 | ▼-0.004 | ▲0.009 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.316 | ▲0.003 | ▲0.047 |
| Working Capital Turnover Ratio | 2.208 | ▲0.026 | ▲0.559 |
| Operating Cash Flow Ratio | 2.180 | ▲0.446 | ▲0.767 |
| Operating Cash Flow Sales Ratio | 0.381 | ▲0.058 | ▲0.103 |
| Free Cash Flow Operating Cash Flow Ratio | 0.955 | ▲0.049 | ▲0.189 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 5.110 | ▲1.442 | ▲1.059 |
| Capital Expenditure Coverage Ratio | 22.146 | ▲11.571 | ▲13.421 |
| Dividend Paid And Capex Coverage Ratio | 22.146 | ▲11.571 | ▲13.421 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 12.504 | ▼-1.167 | ▼-5.220 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.83B | $9.85B | $7.63B | $5.16B | $5.76B | |
| Enterprise value | $11.53B | $9.83B | $7.56B | $4.85B | $5.16B | |
| EV / Sales | 4.97x | 4.53x | 4.13x | 3.01x | 3.60x | |
| EV / Op. cash flow | 13.03x | 14.04x | 22.68x | 13.37x | 12.88x | |
| EV / Free cash flow | 13.65x | 15.50x | 44.37x | 21.62x | 15.33x | |
| EV / EBITDA | 12.50x | 13.67x | 26.69x | 18.99x | 16.77x | |
| Net debt / EBITDA | -0.34x | -0.04x | -0.26x | -1.22x | -1.94x | |
| Current ratio | 3.56x | 3.63x | 3.34x | 4.99x | 5.43x | |
| Income quality | 1.13x | 1.34x | 1.60x | 1.99x | 1.74x | |
| Graham number | $23 | $18 | $10 | $10 | $11 | |
| Graham net-net | $2 | $2 | $2 | $3 | $4 | |
| Tax burden | 83.1% | 76.5% | 80.7% | 77.8% | 78.6% | |
| Interest burden | 105.4% | 98.8% | 100.0% | 100.0% | 100.0% | |
| Working capital | $1.04B | $1.06B | $923.7M | $1.29B | $1.50B | |
| Invested capital | $1.54B | $1.49B | $1.46B | $1.70B | $1.66B | |
| Return on assets | 27.5% | 17.7% | 7.1% | 5.9% | 8.8% | |
| Operating ROA | 30.1% | 20.5% | 5.7% | 7.1% | 12.1% | |
| Return on tangible assets | 28.1% | 18.1% | 7.2% | 6.1% | 9.1% | |
| Return on equity | 36.2% | 23.2% | 9.2% | 7.3% | 10.5% | |
| Return on invested capital | 29.7% | 18.2% | 5.4% | 5.7% | 9.9% | |
| Return on capital employed | 35.8% | 23.8% | 6.7% | 7.3% | 12.6% | |
| Earnings yield | 6.6% | 5.3% | 2.7% | 3.5% | 4.0% | |
| Free cash flow yield | 7.1% | 6.4% | 2.2% | 4.3% | 5.8% | |
| Capex / Op. cash flow | 4.5% | 9.5% | 48.9% | 38.2% | 16.0% | |
| Capex / Depreciation | 137.4% | 229.8% | 633.7% | 663.3% | 471.2% | |
| Capex / Sales | 1.7% | 3.1% | 8.9% | 8.6% | 4.5% | |
| SG&A / Sales | 22.4% | 22.7% | 29.7% | 28.5% | 28.0% | |
| R&D / Sales | 35.6% | 42.0% | 57.0% | 55.4% | 48.3% | |
| Stock comp / Sales | 4.9% | 4.3% | 5.8% | 6.7% | 8.4% | |
| Intangibles / Total assets | 2.2% | 2.2% | 2.2% | 2.1% | 2.4% | |
| Days sales outstanding | 45d | 45d | 47d | 49d | 73d | |
| Days payables outstanding | 129d | 183d | 170d | 206d | 167d | |
| Operating cycle | 140d | 152d | 135d | 259d | 262d | |
| Cash conversion cycle | 11d | -31d | -35d | 53d | 95d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-13 Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL) Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell Exelixis reported an adjusted earnings beat of $0.91 per share for the second quarter. Revenue came in at approximately $628.7 million -- below Wall Street consensus -- and the stock fell
- 2026-08-12 EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL) NEW YORK--(BUSINESS WIRE)--Exelixis (NASDAQ: EXEL) shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. If you suffered a loss on your Exelixis investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The revenue shortfall came alon.
- 2026-08-11 EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of EXEL shareholders.
- 2026-08-10 Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL) On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell.
- 2026-08-08 Arkadios Wealth Advisors Purchases New Position in Exelixis, Inc. $EXEL Arkadios Wealth Advisors bought a new position in Exelixis, Inc. (NASDAQ: EXEL) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,098 shares of the biotechnology company''s stock, valued at approximately $476,000. Other hedge funds and other institutional investors have also bought and sold shares
- 2026-08-08 Amundi Sells 121,348 Shares of Exelixis, Inc. $EXEL Amundi cut its position in Exelixis, Inc. (NASDAQ: EXEL) by 77.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,398 shares of the biotechnology company''s stock after selling 121,348 shares during the quarter. Amundi''s holdings in Exelixis were worth $1,475,000 at
- 2026-08-06 EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers ''26 View Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET launch weighs on expectations.
- 2026-08-05 Exelixis Q2 Earnings Call Highlights Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program for the drug candidate.
- 2026-08-05 Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-05 Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript